Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.53 EUR
Change Today +0.029 / 1.93%
Volume 0.0
IM3 On Other Exchanges
As of 12:13 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

300 The American Road

Morris Plains, NJ 07950

United States

Phone: 973-605-8200

Fax: 973-605-8282

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. Clinical Programs The company focuses its activities on unlabeled, or ‘naked’ antibodies and antibodies conjugated with drugs, cytokines, or toxins, and on the use of radioisotopes, such as such as yttrium-90 (90Y). Yttrium-90-Labeled Clivatuzumab Tetraxetan: 90Y-clivatuzumab tetraxetan is the company’s therapeutic product candidate for patients with pancreatic cancer. Clivatuzumab tetraxetan is the conjugation of hPAM4, an antibody that targets a mucin antigen found on pancreatic cancer cells, with a linker that could be radiolabeled with 90Y and other radioisotopes. This product candidate utilizes radioimmunotherapy, which combines the targeting power of monoclonal antibodies with the cell-damaging ability of localized radiation. The company has begun patient enrollment into its Phase 3 registration study (PANcreatic Cancer RadioImmunotherapy Trial-1: PANCRIT-1) in patients with metastatic pancreatic cancer who have received at least two prior therapies, one of which must have been a gemcitabine-containing regimen. Antibody-Drug Conjugates (ADCs): The company has two product candidates from its proprietary ADC program that are in clinical development, focusing on the treatment of patients with metastatic solid tumors. The first ADC program, sacituzumab govitecan, is an anti-TROP-2-SN-38 ADC being evaluated in patients with various solid tumors. Labetuzumab govitecan is an anti-CEACAM5-SN-38 ADC that is in development for the treatment of mCRC. Sacituzumab govitecan or IMMU-132: Sacituzumab govitecan is an ADC that contains SN-38, the active metabolite of irinotecan, approved by Health Authorities, including the U.S. Food and Drug Administration (FDA), as a chemotherapeutic for patients with cancer. Sacituzumab govitecan was created at the company by conjugating SN-38 site-specifically and at a high ratio of drug to hRS7, its anti-TROP-2 antibody. Sacituzumab govitecan has received Fast Track designation from FDA for the treatment of patients with TNBC who have failed prior therapies for metastatic disease and for patients with small-cell lung cancer (SCLC), or non-small-cell lung cancer (NSCLC). This ADC also has been designated an orphan drug by FDA for the treatment of patients with SCLC or pancreatic cancer in the U.S. and by the European Medicines Agency (EMA) for the treatment of patients with pancreatic cancer in the European Union. Labetuzumab Govitecan or IMMU-130: The company’s second investigational solid-tumor ADC involves its anti-CEACAN5 antibody, labetuzumab, conjugated to SN-38. The agent is being studied in patients with mCRC who had received at least one prior irinotecan-containing regimen and had an elevated blood titer of carcinoembryonic antigen (CEA). Epratuzumab: Epratuzumab is a humanized antibody which targets CD22, an antigen found on the surface of B lymphocytes, a type of white blood cell critical to proper immune system function. Early-Stage Programs The company has additional potential products for the treatment of cancer and autoimmune diseases, including veltuzumab, its anti-CD20 antibody, and milatuzumab, its anti-CD74 antibody. Veltuzumab is being evaluated in a Phase 2 study in combination with 90Y-epratuzumab tetraxetan in patients with aggressive NHL, funded by a grant from the Small Business Innovation Research (SBIR) program of the National Cancer Institute (NCI). Milatuzumab has received a Department of Defense grant for a clinical study in patients with lupus. The company also collaborates with the University Hospital in Nantes, France, which is conducting a multicenter study testing its bispecific pretargeting technology, co-developed with its majority-owned subsidiary, IBC Pharmaceuticals, Inc., as a potentially improved method of detecting and locating sites of metastatic breast cancer. Veltuzumab Veltuzumab is a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes under development for the treatment of non-Hodgkin lymphoma (NHL) and autoimmune


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM3:GR €1.53 EUR +0.029

IM3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IM3.
View Industry Companies

Industry Analysis


Industry Average

Valuation IM3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at